Michael Wang, MD

Articles

Dr. Wang on the Results of the Phase 3 SHINE Study in MCL

June 3rd 2022

Michael Wang, MD, discusses the results of the phase 3 SHINE trial in older patients with mantle cell lymphoma.

Dr. Wang on Adverse Effects of BTK Inhibitors in MCL

March 1st 2022

Michael Wang, MD, discusses adverse effects associated with BTK inhibitors in patients with mantle cell lymphoma.

Clinical Pearls in the Management of Marginal Zone Lymphoma

February 25th 2022

Closing out their discussion on B-cell malignancies, expert panelists share clinical pearls on the management of marginal zone lymphoma.

Novel Treatment Strategies for Relapsed/Refractory MZL

February 25th 2022

A comprehensive review of novel therapies in relapsed/refractory marginal zone lymphoma and possible sequencing strategies in this setting.

Dr. Wang on Potential Adverse Effects of Ibrutinib in MCL

February 24th 2022

Michael Wang, MD, discusses potential adverse effects associated with ibrutinib in patients with mantle cell lymphoma.

Dr. Wang on Sequencing Oral Agents in MCL

February 23rd 2022

Michael Wang, MD, discusses the sequencing of oral therapies in mantle cell lymphoma.

Frontline Treatment Options for Marginal Zone Lymphoma

February 18th 2022

Shared insight on frontline treatment approaches for patients diagnosed with marginal zone lymphoma.

Clinical Pearls in the Management of Follicular Lymphoma

February 18th 2022

Clinical pearls for community physicians regarding the optimal management of patients with follicular lymphoma.

Dr. Wang on the Evolution of Ibrutinib in the Treatment Landscape of MCL

February 14th 2022

Michael Wang, MD, discusses the evolution of ibrutinib in the treatment landscape of mantle cell lymphoma.

Optimizing the Sequencing of Therapy in Follicular Lymphoma

February 11th 2022

Panelists use an illustrative clinical case to comprehensively discuss the selection and sequencing of therapies for patients with follicular lymphoma.

PI3K Inhibitors in Relapsed/Refractory Follicular Lymphoma

February 11th 2022

A review of the role of PI3K inhibitors in the treatment of follicular lymphoma, and how they have been used to improve patient outcomes.

Dr. Wang on the Evolving Treatment Landscape of MCL

February 9th 2022

Michael Wang, MD, discusses the evolving treatment landscape of mantle cell lymphoma.

Novel Therapies and Treatment Selection in Patients With Relapsed/Refractory FL

February 4th 2022

Expert perspectives on novel approaches to treatment in the relapsed/refractory setting, particularly CAR T-cell therapy, for patients with follicular lymphoma.

Pathophysiology of Follicular Lymphoma and Frontline Therapy

February 4th 2022

Shared insight on the indolent nature of follicular lymphoma and frontline therapy options for this disease.

Clinical Pearls in the Management of Mantle Cell Lymphoma

January 28th 2022

Closing out their discussion on mantle cell lymphoma, expert panelists share clinical pearls for practicing community physicians.

Optimizing MCL Management: Sequencing and Combination Strategies

January 28th 2022

Panelists use an illustrative clinical case to highlight best practices in sequencing therapy for mantle cell lymphoma and discuss novel combination strategies under investigation.

CAR T-cell Therapy in Relapsed/Refractory Mantle Cell Lymphoma

January 21st 2022

A brief review of CAR T-cell therapy in relapsed/refractory mantle cell lymphoma as studied in the ZUMA-2 clinical trial of brexucabtagene autoleucel.

Second-Line Therapy for MCL: Differentiating Available BTK Inhibitors

January 21st 2022

Moving to second-line therapy for mantle cell lymphoma, experts discuss available BTK inhibitors, including the novel agent pirtobrutinib.

Considerations for Selection and Use of Frontline Therapy in Mantle Cell Lymphoma

December 23rd 2021

Shared insight on the optimal selection and use of frontline therapy for patients who present with mantle cell lymphoma.

An Overview of Mantle Cell Lymphoma and Frontline Therapy

December 23rd 2021

Expert panelists discuss a number of recent updates in B-cell lymphoma, particularly mantle cell lymphoma, follicular lymphoma and marginal zone lymphoma, that were presented at key conferences in 2021.